References
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–12. doi:https://doi.org/10.1038/nrc3236.
- Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs. 2019;11(2):219–38. doi:https://doi.org/10.1080/19420862.2018.1556465.
- Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018 Nature Publishing Group;36(12):1136–45. doi:https://doi.org/10.1038/nbt.4305.
- Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly A, Ledermann JA, Glaser MG, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/IL study with comparative biodistribution of intact and F(Ab’) antibodies. Br J Cancer. 1994;7:521–25. doi:https://doi.org/10.1038/bjc.1994.338.
- Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals. 2018;11:32.
- Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711–16.
- Lustgarten J, Cui Y, Li S. Targeted cancer immune therapy. Springer: Springer New York; 2009.
- Zagzag D, Frdlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M and Greco MA et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 1995;55(4):907–14.
- Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L and Neri D. Human monoclonal antibodies to domain C of Tenascin-C selectively target solid tumors in vivo. Protein Eng Design Select. 2006;19:471–78. doi:https://doi.org/10.1093/protein/gzl033.
- Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L and Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer. 2008;122:2405–13. doi:https://doi.org/10.1002/ijc.23408.
- Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, and Neri. Design and use of a phage display library. J Biol Chem. 1998;34:21769–76. doi:https://doi.org/10.1074/jbc.273.34.21769.
- Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of Tenascin-C. Clini Cancer Res. 2006;12:3200–08. doi:https://doi.org/10.1158/1078-0432.CCR-05-2804.
- Midwood KS, Hussenet T, Langlois B, Orend G. Advances in Tenascin-C biology. Cell Mol Life Sci. 2011;68:3175–99.
- Tucker RP, Chiquet-Ehrismann R. Tenascin-C: its functions as an integrin ligand. Int J Biochem Cell Biol. 2015;65:165–68. doi:https://doi.org/10.1016/j.biocel.2015.06.003.
- Dobbertin A, Czvitkovich S, Theocharidis U, Garwood J, Andrews MR, Properzi F, Lin R, Fawcett JW, Faer A. Analysis of combinatorial variability reveals selective accumulation of the fibronectin type III domains B and D of Tenascin-C in injured brain. Exp Neurol. 2010;225(1):60–73. doi:https://doi.org/10.1016/j.expneurol.2010.04.019.
- Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular pH controls pre-mRNA alternative splicing of Tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer. 1996;66(5):632–35.
- Giblin SP, Midwood KS. Tenascin-C: form versus function. Cell Adh Migr. 2015;9(1–2):48–82. doi:https://doi.org/10.4161/19336918.2014.987587.
- Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia. 1995;51(9–10):853–62. doi:https://doi.org/10.1007/BF01921736.
- Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796–805.
- Balza E, Siri A, Ponassia M, Caocci F, Linnala A, Virtanen I, Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. Eur Biochem Soc. 1993;332:39–43. doi:https://doi.org/10.1016/0014-5793(93)80479-E.
- Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, Baralle F, Zardi L. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res. 1991;19(3):3525–3231. doi:https://doi.org/10.1093/nar/19.3.525.
- Riva P, Sturiale AA, Sturiale C, Moscatelli G, Tison V, Mariani M, Seccamani E, Lazzari S, Fagioli L, Franceschi G. Treatment of intracranial human glioblastoma by direct intratumoral administration of 1311-labelled anti-Tenascin monoclonal antibody BC-2. Int J Cancer. 1992;51:7–13. doi:https://doi.org/10.1002/ijc.2910510103.
- Riva P, Arista A, Franceschi G, Frattarelli M, Sturiale C, Riva N, Casi M, Rossitti R. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55:5952–56.
- Paganelli G, Magnani P, Zito F, Lucignan G, Sudati F, Truci G, Motti E, Terreni M, Pollo B, Giovanelli M. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med. 1994;21(4):314–32. doi:https://doi.org/10.1007/BF00947966.
- Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.. J clin oncol. 1998;16(6):2202–12. doi:https://doi.org/10.1200/JCO.1998.16.6.2202.
- Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, et al. A pilot study: 131I-AntiTenascin monoclonal antibody 81C6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 2008;10(2):182–89. doi:https://doi.org/10.1215/15228517-2007-053.
- He X, Archer GE, Wikstrand CJ, Morrison SL, Zalutsky MR, Bigner DD, Batra SK. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol. 1994;52(2):127–37. doi:https://doi.org/10.1016/0165-5728(94)90106-6.
- Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004;104(3):642–48. doi:https://doi.org/10.1182/blood-2003-12-4264.
- De Santis R, Anastasi AM, D’Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, et al. Novel antiTenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioimmunoTherapy (PAGRITR). Br J Cancer. 2003;88(7):996–1003. doi:https://doi.org/10.1038/sj.bjc.6600818.
- Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G. et al. Improved tumor targeting by combined use of two antiTenascin antibodies. Clini Cancer Res. 2005;11:7137–45. doi:https://doi.org/10.1158/1078-0432.CCR-1004-0007.
- Rami A, Behdani M, Yardehnavi N, Habibi-Anbouhi M, Kazemi-Lomedasht F. An overview on application of phage display technique in immunological studies. Asian Pac J Trop Biomed. 2017;6:599–602. doi:https://doi.org/10.1016/j.apjtb.2017.06.001.
- Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12(1):433–55. doi:https://doi.org/10.1146/annurev.iy.12.040194.002245.
- Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM and Hashem AM. Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol. 2020;11.
- Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. mAbs. 2016;8(7):1177–94. doi:https://doi.org/10.1080/19420862.2016.1212149.
- Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016;40:96–102. doi:https://doi.org/10.1016/j.coi.2016.03.006.
- Neri D. Antibody–cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immunol Res. 2019;7:348–54. American Association for Cancer Research Inc.
- Pasche N, Neri D. Immunocytokines: A novel class of potent armed antibodies. Drug Discov Today. 2012;17(11–12):583–90. doi:https://doi.org/10.1016/j.drudis.2012.01.007.
- List T, Neri D. Immunocytokines: A review of molecules in clinical development for cancer therapy. Clin Pharm Adv Appl. 2013;5:29–45.
- Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW, et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014;5(7):1869–84. doi:https://doi.org/10.18632/oncotarget.1853.
- Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clini Cancer Res. 2012;18(15):4092–103. doi:https://doi.org/10.1158/1078-0432.CCR-12-0282.
- Huston JS, Levinson D, Mudgett-Huntert M, Tai M-S, Novotnt J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci. 1988;85:5879–83. doi:https://doi.org/10.1073/pnas.85.16.5879.
- Dwyer G, Mccomas W, Familletti PC, Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Gately MK, Gubler U. Cloning and expression of murine IL-12. J Immunol. 1992;148:3433–40.
- Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, Viti F, Neri D. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5(9):2340–50. doi:https://doi.org/10.1002/pmic.200401273.
- Fairhead M, Howarth M. Site-specific biotinylation of purified proteins using BirA. Methods Mol Biol. 2015;1266:171–84.
- Gébleux R, Stringhini M, Casanova R, Soltermann A, Neri D. Non-internalizing antibody–drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer. 2017;140:1670–79. doi:https://doi.org/10.1002/ijc.30569.
- Saga Y, Tsukamoto T, Jing N, Kusakabe M, Sakakura T. Murine Tenascin: cDNA cloning, structure and temporal expression of isoforms. Gene. 1991;104(2):177–85. doi:https://doi.org/10.1016/0378-1119(91)90248-A.
- Thoring L, Dondapati SK, Stech M, Wüstenhagen DA, Kubick S. High-yield production of “difficult-to-express” proteins in a continuous exchange cell-free system based on CHO cell lysates. Sci Rep. 2017;7(1):11710. doi:https://doi.org/10.1038/s41598-017-12188-8.
- Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):315–29. doi:https://doi.org/10.1016/S1470-2045(17)30194-8.
- Puca E, Probst P, Stringhini M, Murer P, Pellegrini G, Cazzamalli S, Hutmacher C, Gouyou B, Wulhfard S, Matasci M, et al. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer. 2020;146(9):2518–30. doi:https://doi.org/10.1002/ijc.32603.
- Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031–43. doi:https://doi.org/10.1158/0008-5472.CAN-17-1788.
- Weber M, Bujak E, Putelli A, Villa A, Matasci M, Gualandi L, Hemmerle T, Wulhfard S, Neri D. A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS ONE. 2014;9(6):6. doi:https://doi.org/10.1371/journal.pone.0100000.
- Beckett D, Kovaleva E, Schatz PJ. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 1999;8:921–29. doi:https://doi.org/10.1110/ps.8.4.921.
- Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol. 2011;154:84–92. doi:https://doi.org/10.1016/j.jbiotec.2011.04.003.
- Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Method Enzymol. 2000;326:480–505.
- Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M, Roth P. NKG2D-Dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clini Cancer Res. 2018;24(4):882–95.s. doi:https://doi.org/10.1158/1078-0432.CCR-17-1766.